On biotech platform strategy
1/ 🧬 How to Price a Platform in Biotech
Q2 M&A is ripping, Capstan just cleared $2.1B at Phase 1, and something important has changed.
A new market dynamic may be emerging, where optionality matters again.
Let’s break it down with math, comps, and a framework 🧵... See more
GLP1s have added $1T in market cap to Eli and Novo over the last 5 years. That's 3x+ the market cap created by all biopharma startups over the last 30 years combined. This is a bit of an indicment of the biotech startup ecosystem. There are many $1T and even $10T drugs to be invented, we just don't fund them. Through no one persons fault, the... See more
Blake Byersx.comHeard from a seasoned biotech exec: “We have a platform – not just multiple shots on goal.” This is an important distinction. How do teams convince investors that they have a unique platform that could truly spit out dozens of drug candidates? A few thoughts. 1/12
Sara Nayeemx.com